Auren Rx: August 2026 Investigation and Current Review

Auren Rx now has a graded review: 72.9/100, grade C. Read the current Auren Rx scorecard for the six factor scores and the full caveats.

Current provider record

Semaglutide: $149/mo (auto-refill; a single month with no commitment is $179). Tirzepatide: $149/mo (auto-refill; a single month with no commitment is $179).

Coverage recorded in the graded review: All 50 states. The provider record's merchant-verification date is 2026-09-01. This article was reconciled with that existing record on October 6, 2026; this is not a new merchant verification. The August findings below do not establish today's checkout price or resolve every previously documented discrepancy.

The current review records these caveats: The $149 figure requires enrolling in auto-refill; a single month with no commitment is $179. Two different medical groups are named for the same service — Wasef Health, PC on the contact page and FAQ, Beluga Health, P.A. in the telehealth consent.

Historical investigation — August 7, 2026

The following investigation records what our August pass found. Its prices, availability, named providers and policies describe that pass, not current offers. Each section is dated to keep those historical observations separate from the current record above. The original citations remain attached to the observations they supported.

There is a specific thing we look for on a provider's product page and almost never find: two prices, side by side, one for committing and one for not. Auren Rx (aurenrx.com) prints both on every single item it sells. It is the cleanest price surface of the seven companies we checked in August 2026, and it is attached to the largest single disclosure hole in the group. Those were findings from the August price-and-disclosure pass. The current graded review, linked above, applies the six weighted dimensions in our methodology.

August 2026: The two-rung structure

Standard semaglutide is $199 a month with no commitment, or $169 a month on a subscription. Standard tirzepatide is $299 with no commitment, $259 subscribed. There is a separate, named microdose program: semaglutide at $149 monthly or $129 subscribed, tirzepatide at $250 monthly or $229 subscribed.

We file the no-commitment numbers — $199 and $299 — because that is what the product costs if you do not sign anything. The company's own structured data does not. Its product markup emits the subscribe rung, which means any price aggregator scraping the page records $169 and $259 and never sees the monthly rate. That is worth knowing if you find Auren Rx quoted somewhere cheaper than this page quotes it; the difference is not a discount you missed, it is a different rung.

Around the GLP-1s the same two-rung structure holds. NAD+ runs $209 a month for the 10 mL injection, $169 to $249 across four nasal-spray strengths and sizes, $155 or $215 for the 10 percent cream. Sermorelin is $199. Glutathione is $119 injected or $109 nasal. GHK-Cu cream is $109, tretinoin $49, oral minoxidil $49, valacyclovir $39 or $49, estradiol $69 to $99 depending on patch or tablet. Every one of those is the monthly, no-commitment figure. That NAD+ line is unusually granular — most sellers publish one number for a category and leave route and strength to your imagination. If route matters to you, oral vs. injectable GLP-1 covers why it does more than most buyers expect.

August 2026: Two ways to misread this site

The weight-loss page ships with its molecule selector defaulting to tirzepatide, not semaglutide. Land on the page, read the price, write it down, and you have recorded tirzepatide's number under semaglutide's name — a column shift, one of the standard capture errors on our cost dimension. It is a live example of why we normalize prices from the underlying data instead of from whatever the page happens to be showing.

The second is the navigation, which reads that semaglutide and tirzepatide start from $129 a month. That $129 is real, but it is the microdose semaglutide subscribe rung. Under a heading naming both molecules it understates standard GLP-1 by $70 a month. Not a fabricated number, and not a rate you can buy for a standard program.

August 2026: The hole

Auren Rx never publishes the states it serves. Not a list, not a map, not a lookup. The terms say certain services are available only to individuals located in certain states, and refer elsewhere to "a state where we operate", and that is the whole of it.

Every other company in this pass discloses something on this — a 36-state list, a 50-state claim with named video-visit exceptions, even a bare 50-state assertion. This one discloses nothing, and it matters more than a missing paragraph usually would, because state availability is the one thing about a telehealth program that can make the entire purchase moot. It is also the answer we cannot supply on your behalf: you find out by starting an intake. That belongs on the same list as the price questions in our six-point checklist, and if you are weighing a cash-pay program against a covered branded one, run it before the math in does insurance cover GLP-1 weight-loss drugs?.

August 2026: Oversight, fulfillment and the entity

The August pages named Beluga Health, P.A. as the medical group. That organization name can support a registry search even without a published NPI. No individual prescriber was identified on the reviewed pages, and we did not establish an exact organization match or the assigned clinician's identity. An NPI is not proof of licensure or credentials; a state-board license check is separate. The dispensing pharmacy is never named individually; the site refers to its own pharmacy network, and notes that you may elect a local pharmacy instead, in which case the membership fee excludes medication cost. The legal entity is Hades Capital LLC, doing business as Auren RX, with no address published.

Two products, valacyclovir and estradiol, are missing from the site's own sitemap. That is a housekeeping detail rather than a red flag, but it is the reason a catalog read from a sitemap alone would have been wrong about what this company sells.

August 2026: Contract terms, which are unusually well behaved

The membership is month-to-month and cancellable at any time by email or in the account. It can be paused, with no further charges until you order a refill. There is no prepay tier at all, which removes an entire family of pricing traps. Billing is disclosed as approximately every 28 to 30 days — slightly short of a calendar month, and disclosed, which is the part that matters. Compare that with Vyvron, which bills on a four-week cycle while printing "/mo".

The one term to read twice: the membership fee is charged the day membership commences and is non-refundable once paid. Membership begins after a provider communicates a care plan and you elect to proceed, so it follows clinical review rather than preceding it — a better sequence than most of this cohort. Non-refundable is still non-refundable. The product pages also carry star ratings with no review count and no source attached; we are not reprinting them, and neither should any ranking.

August 2026: The regulatory screen

The FDA's live warning-letter index returned no company-column match in August 2026 for Auren Rx, for Hades Capital, or for Beluga Health. The same pass returned a known February 2026 letter for an unrelated telehealth seller run as a positive control, so the zeros are evidence rather than a query that failed silently.

August 2026: Questions left by the original investigation

The August pass left state availability, the pharmacy identity and the clinical disclosures as questions to resolve. It also documented a complete published price ladder, a no-commitment rung, no prepay tier and a stated billing cadence. The later graded review has different prices and additional disclosures; consult that record rather than treating this historical account as the current offer. The original parallel investigations of The Edit and Trellis Vitality remain available for context.